INO-5401: Clinical Trials

3 trials of INO-5401, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Active not recruiting 2, Completed 1
Phase 22Active not recruiting 1, Completed 1

Follow INO-5401: new trials by email Literature Review of INO-5401 trials Research Report on INO-5401

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
INO-5401, INO-9012, Cellectra 2000 - BRCA1/2 Mutation
Phase 1Active not recruitingUniversity of Pennsylvania442021-04-202026-10-21
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma
Phase 1 / Phase 2CompletedInovio Pharmaceuticals352018-07-242026-09-02
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
INO-5401, INO-9012, Cemiplimab - Glioblastoma
Phase 1 / Phase 2Active not recruitingInovio Pharmaceuticals522018-05-312026-10-22

Conditions studied

Carcinoma, Transitional Cell (1)  ·  Glioblastoma (1)

Sponsors

Inovio Pharmaceuticals (2)  ·  University of Pennsylvania (1)

Countries

United States (3)

Top investigators

Jeffrey Skolnik, MD (2)  ·  Susan Domchek, MD (1)

Results publications

PMID 38991631